Peritoneal Dialysis International最新文献

Peritoneal dialysis (PD) and kidney transplantation are important therapeutic options in patients with advanced kidney disease. This article delineates the relationship between PD and kidney transplantation in several key domains, including: (1) Comparative merits and limitations of PD versus center-based hemodialysis prior to kidney transplantation, (2) Patient outcomes after kidney transplantation in individuals receiving PD prior to kidney transplantation, (3) Perioperative management strategies of patients receiving PD at the time of kidney transplantation, and (4) The relative advantages and clinical outcomes of PD use following kidney allograft failure compared to other modalities. This article aims to provide comprehensive guidance for optimizing care across the PD-kidney transplant transitions continuum.

There is growing emphasis on increasing utilization of peritoneal dialysis (PD) in patients with end stage kidney disease (ESKD); however, use in patients with severe obesity has still been fraught for various reasons. We aim to assess the viability of PD in patients with severe obesity (BMI > 40 Kg/m²). We conducted a retrospective chart review of patients admitted at the home dialysis center of an academic center between 2014 and 2020 (n = 99). Patients with a BMI>40 kg/m² at the time of PD initiation (n = 9) were selected. We extracted and examined the data for these nine patients till March 2023. The mean age at baseline was 47.8 ± 12.6 year, 56% were males, 67% were Hispanic, 33% were white, and mean BMI was 43.3 ± 3.4 kg/m². By the end of the follow-up of this report, five (56%) patients were still active on PD (mean duration 27.8 ± 4.5 months). PD therapy was terminated in 3 (33%) patients (17.7 ± 6.8 months) due to refractory peritonitis, burnout, transfer to rehabilitation facility, respectively. One patient transferred out to another facility after 10.6 months. Rates of access and mechanical complications as well as peritonitis in these nine patients were similar to center's overall rates. All the patients had elimination of uremic symptoms using incremental prescription and met weekly Kt/V targets of >1.7 using adjusted weight. Overall, patients' weight and glycemic control remained stable. In conclusion, PD can be an effective long-term high-quality dialysis option for patients with ESKD and severe obesity. Further studies in a larger population are required to confirm our findings.

Background: Few studies have evaluated the predictive capability of equations for residual kidney function (RKF) in patients undergoing peritoneal dialysis (PD). Moreover, the applicability of each equation remains unclear. Therefore, we aimed to evaluate the performances of the estimated RKF (eRKF) equations of Shafi, Steubl, and Jaques in Chinese patients undergoing continuous ambulatory peritoneal dialysis (CAPD).

Methods: This was a retrospective study. We enrolled patients who underwent CAPD and RKF measurements (via 24-h urine collection) in our hospital between November 2021 and May 2022. Using the measured RKF (mRKF) as the reference, we derived the bias, precision and accuracy of each equation.

Results: We enrolled 174 participants. The mean β2-microglobulin and median mRKF were 29.00 ± 8.69 mg/L and 2.94 (1.26, 4.65) mL/min/1.73 m², respectively. The Steubl equation had the least bias (MD [95% confidence interval, CI]: -0.52 [-0.77 to -0.38]), higher precision (interquartile range: 1.43 [1.16, 1.76]), and highest accuracy (83%). It also had a high diagnostic accuracy for identifying patients with an mRKF of > 2.5 mL/min/1.73 m², area under the curve of 0.936 95% CI [0.903-0.970], p < 0.001), cut-off value of 1.80 mL/min/1.73 m², specificity of 0.895, and sensitivity of 0.847.

Conclusion: Although no equation was fully accurate, the Steubl equation identified patients suitable for an incremental PD prescription more accurately than the Shafi and Jaques versions. It may be useful for monitoring the RKF of Chinese patients undergoing CAPD who are unable to reliably collect urine.

Peritoneopericardial leakage is a rare but important complication of peritoneal dialysis. Peritoneal scintigraphy is reported to be effective in diagnosing the peritoneopericardial communication. Although switching to hemodialysis is commonly recommended, reducing exchange volumes and performing peritoneal dialysis in an upright sitting position may also be considered particularly in pediatric patients. Here we presented a 10-year-old girl in whom peritoneopericardial leakage was demonstrated with peritoneal scintigraphy and was successfully managed by conservative approach.

Baclofen is a gamma-aminobutyric acid agonist that is commonly and widely used for the treatment of muscle spasticity. Given its predominant kidney excretion, patients with reduced kidney function are at particular risk of drug accumulation and toxicity, with neurotoxicity in the form of drowsiness, encephalopathy, seizures, and coma being the most reported clinical features. In addition to the importance of early identification of baclofen toxicity and drug discontinuation, dialysis can effectively accelerate baclofen elimination given its small molecule weight, and the relatively low volume of distribution and weak protein binding. While several cases of baclofen-induced toxicity have been reported in hemodialysis patients, the literature on baclofen toxicity in individuals receiving peritoneal dialysis (PD) is limited. Here, we present a case of baclofen-induced encephalopathy in a PD patient following a single dose of baclofen. In this case, our patient was managed by continuous (24 h) automated PD, with complete recovery of neurological status within three days.

Anorexia nervosa (AN) is an eating disorder characterized by restriction of energy intake leading to a significantly low body weight, and intense fear of gaining weight. Severe electrolyte changes such as hypokalemia and hypophosphatemia; and alterations in water metabolism such as hyponatremia and edema, can occur in patients with AN. Hypokalemia and chronic volume depletion may lead to acute kidney injury (AKI) and chronic kidney disease (CKD). There are few reports of patients with AN who require maintenance dialysis. Therefore, it is unclear whether hemodialysis (HD) or peritoneal dialysis (PD) is suitable for such patients. We report a case of kidney failure that developed in the patient with AN who received successful psychiatric treatment aimed at weight gain while performing PD. The safety of PD may be improved in patients who also undergo cognitive behavioral psychotherapeutic intervention.

The global unmet need for kidney replacement therapy means that millions of people die every year as they cannot afford treatment. Peritoneal dialysis (PD) offers comparable survival to haemodialysis and is often more affordable, but one barrier to increasing access is that conventional manufacturing and distribution of PD fluid is costly. Here we report the results from a pilot proof-of-principal study demonstrating for the first time that the Ellen Medical Devices Point-of-Care system can be used by patients to produce sterile PD fluid at the point-of-care. With further development, this low-cost system could offer a solution to the many millions of people around the world who currently cannot afford treatment for kidney failure.